Lenalidomid Grindeks (Lenalidomide)

Lenalidomide exerts its effect by binding to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex. This binding changes the complex’s target specificity, leading to the degradation of transcription factors such as Ikaros and Aiolos. The downstream result is altered cytokine production, inhibition of new blood‑vessel formation, enhanced immune‑cell activity, and direct induction of tumor‑cell apoptosis.

The dose of Lenalidomid Grindeks is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and blood‑count parameters. Treatment regimens are established in clinical practice guidelines and may be adjusted over time according to laboratory monitoring and therapeutic response. Patients should follow the exact dosing instructions provided by their healthcare professional.

Lenalidomid Grindeks is contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception throughout treatment and for a defined period after the last dose. Limited data exist for use while breastfeeding, and the drug is generally not recommended for nursing mothers due to potential exposure to the infant.

To request Lenalidomid Grindeks, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any required temperature control) and assist with import documentation.

The primary alternative to lenalidomide is thalidomide, another immunomodulatory agent. Lenalidomide generally offers a more favorable safety profile, with lower rates of peripheral neuropathy and constipation, while providing stronger anti‑angiogenic and anti‑myeloma activity. However, both drugs share risks such as thrombosis and myelosuppression, and the choice depends on individual patient factors and physician judgment.

Lenalidomid Grindeks should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original packaging to protect it from moisture, light and excessive heat. Do not store in the bathroom or near a kitchen sink, and keep it out of reach of children.

Lenalidomid Grindeks is taken orally, usually as a tablet that should be swallowed whole with a glass of water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber. Consistent daily dosing helps maintain stable drug levels and optimizes therapeutic effect.

The most serious adverse events linked to Lenalidomid Grindeks include venous thromboembolism (blood clots in veins or lungs), severe neutropenia that can predispose to serious infections, and the possible development of secondary primary malignancies. Patients should be monitored closely for signs of clotting, infection, or new cancer diagnoses throughout therapy.

Lenalidomid Grindeks should be avoided in patients who are pregnant, planning to become pregnant, or are breastfeeding. It is also contraindicated in individuals with known hypersensitivity to lenalidomide or any component of the formulation. Caution is advised for patients with severe renal impairment, uncontrolled infections, or a history of thromboembolic events, and the decision to treat should be made by a qualified physician.